

March 31, 2021**Contents**

Clinical Profile: Problems	2
AJCC Staging Updates	2
Updates	2
Lab Analytes & Panels	2
Additions	2
Updates	5
Medications	5
Additions	5
Updates	6
Regimens.....	8
Updates	8
Vinca Alkaloid IV Push Removal.....	8
Infection Prophylaxis	8
Ferumoxytol (Feraheme) Infusion Length	8
Biosimilars	8
Diagnosis Regimen Updates	8
Additions	9
Regimen Inactivations.....	9
Regimen Renames	10
Research.....	10
Regimen Additions.....	10
Updates	10
Vinca Alkaloid IV Push Removal.....	10
Biosimilars	10
USOR Clinical Trial Updates	10
Billing: HCPCS Code Updates	11

Clinical Profile: Problems

AJCC Staging Updates

This release updates **TNM** values, **Stage Groupings** and **Template** functionality for **Cervical Cancer**.

Updates

For **Lung Cancer, Non-small Cell (NSCLC)** the following KRAS gene options are available:

- KRAS G12 activating mutation
- Other KRAS mutation
- Wild type
- Unknown

The problem group **Glioblastoma multiforme (disorder)** is added to **Brain Cancer (Parent)**.

Lab Analytes & Panels

Additions

- ABG panel, POC
- Acetylcholine receptor binding antibody panel
- Acetylcholine receptor blocking antibody panel
- Alveolar O2
- Alveolar O2 tension grad
- Alveolar O2 tension ratio
- Amphiphysin Ab, IFA
- ANA titer 3
- ANNA1 (HU) Ab, IFA
- ANNA2 (RI) Ab, IFA
- ANNA3 Ab, IFA
- Anti-Scl-70 Ab (RDL)
- Anti-Scl-70 Ab (RDL) panel
- Anti-Sm Ab (RDL) panel
- Anti-Sm Ab (RDL), units
- Anti-U1 RNP Ab (RDL) panel
- Anti-U1 RNP Ab (RDL), units
- B. henselae Ab IgG panel
- BCR-ABL1 procedure note
- Bicarbonate, ABG (POC)
- BRCAssure comprehensive additional clinical information
- BRCAssure comprehensive clinical indication
- BRCAssure comprehensive interpretation
- BRCAssure comprehensive methods and limitations
- BRCAssure comprehensive panel
- BRCAssure comprehensive PDF
- BRCAssure comprehensive recommendations
- BRCAssure comprehensive references
- BRCAssure comprehensive released by
- BRCAssure comprehensive specimen type
- CD10 - B-cell
- CD10 - CD45 dim
- CD10 - CD45 neg
- CD10 - granulocytes
- CD10 - monocytes
- CD117 - CD45 dim
- CD117 - CD45 neg
- CD117 – granulocytes
- CD117 - lymphocytes
- CD117 - monocytes
- CD11c - B-cell
- CD11c - CD45 dim

- CD11c - CD45 neg
- CD11c - granulocytes
- CD11c - lymphocytes
- CD11c - monocytes
- CD13 - CD45 dim
- CD13 - CD45 neg
- CD13 - granulocytes
- CD13 - lymphocytes
- CD13 - monocytes
- CD14 - CD45 neg
- CD14 - granulocytes
- CD14 - lymphocytes
- CD14 - monocytes
- CD16 - CD45 dim
- CD16 - CD45 neg
- CD16 - granulocytes
- CD16 - lymphocytes
- CD16 - monocytes
- CD19 - CD45 dim
- CD19 - CD45 neg
- CD19 - granulocytes
- CD19 - lymphocytes
- CD19 - monocytes
- CD19 - Plasma Cells
- CD19+/CD10+ - CD45 dim
- CD2 - CD45 dim
- CD2 - CD45 neg
- CD2 - granulocytes
- CD2 - monocytes
- CD2 - T-Cell
- CD2+CD3+ - lymphocytes
- CD2+CD3+ - T-Cell
- CD20 - CD45 dim
- CD20 - CD45 neg
- CD20 - lymphocytes
- CD20 - monocytes
- CD23 - CD45 dim
- CD23 - CD45 neg
- CD23 – lymphocytes
- CD23 - monocytes
- CD3 - CD45 dim
- CD3 - CD45 neg
- CD3 - granulocytes
- CD3 - lymphocytes
- CD3 - monocytes
- CD3 - T-Cell
- CD33 - CD45 dim
- CD33 - CD45 neg
- CD33 - granulocytes
- CD33 - lymphocytes
- CD34 - CD45 dim
- CD34 - CD45 neg
- CD34 - granulocytes
- CD34 - lymphocytes
- CD34 - monocytes
- CD38 - CD45 dim
- CD38 - CD45 neg
- CD38 - lymphocytes
- CD38 - monocytes
- CD38 - Plasma Cells
- CD4 - CD45 dim
- CD4 - CD45 neg
- CD4 - granulocytes
- CD4 - lymphocytes
- CD4 – monocytes
- CD4 - T-Cell
- CD4+/CD8+ - CD45 dim
- CD4+/CD8+ - granulocytes
- CD4+/CD8+ - monocytes
- CD45 - CD45 dim
- CD45 - CD45 neg
- CD45 - granulocytes
- CD45 - lymphocytes
- CD45 – monocytes
- CD45 - Plasma Cells
- CD5 - B-cell
- CD5 - CD45 dim
- CD5 - CD45 neg
- CD5 - lymphocytes
- CD5 – monocytes
- CD56 - CD45 dim
- CD56 - CD45 neg
- CD56 - granulocytes
- CD56 - lymphocytes
- CD56 - Plasma Cells
- CD56+CD3- - lymphocytes

- CD64 - CD45 dim
- CD64 - CD45 neg
- CD64 - granulocytes
- CD64 - lymphocytes
- CD64 - monocytes
- CD7 - CD45 dim
- CD7 - CD45 neg
- CD7 - lymphocytes
- CD7 - monocytes
- CD8 - CD45 dim
- CD8 - CD45 neg
- CD8 - lymphocytes
- CD8 - monocytes
- Cefotaxime+Clavulanate
- cefTAZidime susc isolate
- cefTAZidime+Clavulanate susc isolate
- Chitotriosidase for Gaucher's panel
- CMV PCR procedural note
- Copper, whole blood, ug/mL
- Creatine panel, serum
- CRMP5/CV2 Ab, IFA
- Delivery system, ABG
- Epstein Barr Virus early antigen (D) panel, IgG
- EtG/EtS, urine, LC/MS/MS, qual
- Ethyl glucuronide, urine, LC/MS/MS
- Ethyl glucuronide, urine, LC/MS/MS note
- Ethyl glucuronide, urine, qual
- Ethyl glucuronide/Ethyl sulfate (EtG/EtS) LC/MS/MS panel
- Ethyl sulfate, urine, LC/MS/MS
- Ethyl sulfate, urine, qual
- Factor VII activity clotting panel
- Factor VII activity, clotting, %
- Flow - cell yield
- Flow (Flow Differential (%)) - CD34+
- Flow (Flow Differential (%)) - CD45 Dim
- Flow -specimen viability
- Giardia Ag panel, stool
- HBsAg quant, IU/mL Helicobacter pylori antibody panel, IgA
- Helicobacter pylori antibody panel, IgM
- Hepatitis BE Ag and Ab panel
- Hepatitis E Ab panel, IgG
- Hepatitis E Ab panel, IgM
- Histiocytes #/100 WBC, body fluid
- HLA-DR - CD45 dim
- HLA-DR - CD45 neg
- HLA-DR - granulocytes
- HLA-DR - lymphocytes
- HLA-DR - monocytes
- IgG subclass 1 panel
- Immunofixation (IFE) IgA, mg/dL
- Immunofixation (IFE) IgG, mg/dL
- Immunofixation (IFE) IgM, mg/dL
- Immunofixation (IFE) serum panel
- JAK2 Exons 12-15 mutation analysis PCR panel
- Kappa - lymphocytes
- Kappa/Lambda - lymphocytes
- Kappa/Lambda light chains, free w/ratio, reflex to IFX panel
- Lambda - lymphocytes
- Liver-kidney microsomal (LKM) antibody panel
- M spike alpha 1
- M spike alpha 2
- M spike beta 1
- M spike beta 2
- M spike gamma 1
- M spike gamma 2
- M spike gamma 3
- M Spike panel
- Meter number, ABG
- Multiple Myeloma, daratumumab-specific, immunofixation interpretation
- Multiple Myeloma, daratumumab-specific, immunofixation panel
- Myoglobin urine panel
- Neutrophil band, Ab, cells/uL
- PCA TR (DNER) Ab, IFA
- PCA1 (YO) Ab, IFA
- PCA2 Ab, IFA
- PEEP, ABG (POC)
- pH panel, stool
- pH, stool
- Posaconazole panel
- PTH Ab panel
- Resin T3 uptake, ratio

- TCO2 (calculated), ABG
- Tissue IFA observation(s)
- Toxoplasma gondii PCR qual panel
- Toxoplasma gondii PCR quant panel
- Toxoplasma gondii PCR, qual
- Trypanosoma cruzi Ab IgG panel
- Tumor necrosis factor-alpha highly sensitive panel
- User, ABG
- VDRL panel
- Vitamin B1 panel, plasma
- West Nile Virus Ab, IgG, IgM panel
- West Nile Virus Ab, IgM panel
- Zonisamide panel

Updates

- BRCAssure comprehensive result
- Hepatitis BE antibody, qual
- IgG, Subclass (total)
- Immunofixation, serum, interpretation
- Immunoglobulins A/E/G/M, serum panel
- Multiple marker panel
- Paraneoplastic Ab evaluation panel w/Reflex to titer/LB, basic
- PEEP
- pH, feces
- SARS CoV-2 semi-quantitative total Ab, spike panel
- SARS CoV-2 semi-quantitative total Ab, U/mL
- Standard Leukemia/Lymphoma bone marrow panel
- Standard Leukemia/Lymphoma comments, bone marrow
- T4 panel
- Von Willebrand factor multimer panel

Medications

Additions

- 2-Deoxy-5-Azacytidine invest IV
- ASB183/GSK2110183 invest IV
- Asciminib (ABL001) invest Oral
- Atezolizumab or Placebo, inj [supplied by sponsor]
- BEC2/BCG vaccine invest Intradermal
- Bempegaldesleukin invest IV
- Bone marrow PSC transplant, allogeneic
- Bone marrow PSC transplant, autologous
- Dr. Rastogi's mouthwash Oral Liquid
- Encequidar invest Oral
- Glucometer Lancet Intradermal
- Glucometer Monitor
- Glucometer Test Strip
- Insulin Pen Needle
- Maltose 10% invest IV
- Pamiparib invest Oral
- PF-06946860 invest Subcutaneous
- RAV12 invest IV
- Syringe 3mL
- Syringe w-needle,disposable,3ml
- Tetrodotoxin invest Subcutaneous
- Triapin invest IV
- Zolbetuximab invest IV

Updates

Drug Name	Change
AZD1775 invest Oral	Added alias Adavosertib invest
Cabotegravir-Rilpivirine IM ER Susp 200 mg/mL-300 mg/mL	Added Quick Sigs : <ul style="list-style-type: none"> • 4 mL intramuscularly once • 6 mL intramuscularly once • 6 mL intramuscularly once • CABOTEGRAVIR: Inject 2 mL (400 mg) intramuscularly once monthly • RILPIVIRINE: Inject 2 mL (600 mg) intramuscularly once monthly • 4 mL intramuscularly once • CABOTEGRAVIR: Inject 3 mL (600 mg) intramuscularly once • RILPIVIRINE: Inject 3 mL (900 mg) intramuscularly once • 6 mL intramuscularly once • CABOTEGRAVIR: Inject 3 mL (600 mg) intramuscularly once • RILPIVIRINE: Inject 3 mL (900 mg) intramuscularly once
Casirivimab-Imdevimab IV Dose Pack 120 mg/mL-120 mg/mL (EUA)	Added Casirivimab-Imdevimab 2,400 mg intravenously Piggyback As Directed; infuse 1,200 mg CASIRIVIMAB and 1,200 mg INDEVIMAB (2,400 mg total dose) together as a SINGLE infusion over at least 60 minutes
DSP-7888 Emulsion invest Intradermal	Added alias Ombipepimut-S Emulsion invest
Gallium Ga-68 Dotatoc IV 18.5 MBq to 148 MBq/mL	Added: <ul style="list-style-type: none"> • 0.1 mCi infuse via intravenous drip once • 0.1 mCi infuse via intravenously Infusion (Drip) once • 0.1 mCi infuse via intravenously push
GSK3326595 invest Oral	Added Form GSK3326595 invest 100 mg Tablet
Levothyroxine Oral	Set default Form to 25 mcg tablet orally every day
Lutetium Lu 177 Dotatate IV 10 mCi/mL (370 mBq/mL)	Added: <ul style="list-style-type: none"> • 1 mCi intravenously Infusion (Drip) once • 1 mCi intravenously Piggyback once
NKTR-214 invest IV	Added Quick Sigs : <ul style="list-style-type: none"> • 0.003 mg/kg intravenously every 3 weeks • 0.006 mg/kg intravenously every 3 weeks • 0.01 mg/kg intravenously every 3 weeks • 1.1 mg/kg intravenously every 3 weeks
Radium Ra 223 Dichloride IV	Added: <ul style="list-style-type: none"> • 1 mCi once infuse via intravenous drip once • 1 mCi once infuse via intravenously Infusion (Drip) once • 1 mCi once infuse via intravenously Piggyback once

Drug Name	Change
Vinblastine IV	<ul style="list-style-type: none"> Removed Quick Sigs with Intravenously Push Route Added Instructions "FATAL IF GIVEN INTRATHECALLY. FOR IV USE ONLY" Is a vesicant
Vincristine IV	
Vinorelbine IV	
XMT-1536 invest IV	Added Form XMT-1536 invest 80 mg lyophilized powder for recon soln

Drug Name	New Maximum Single Dose	Rounding Rule
Abatacept Subcutaneous	125 mg	
Abatacept Subcutaneous Auto-Injector	125 mg	
Alemtuzumab IV 12 mg/1.2 mL	12 mg	
Asparaginase (Erwinia chrysanthemi) IV	63000 units	
Asparaginase (Erwinia chrysanthemi) IM	63000 units	
Bleomycin Intrapleural	60 units	
Cisplatin Intra-Arterial		None
Deferoxamine IM	1000 mg	
Deferoxamine Subcutaneous	1000 mg	
Dexrazoxane IV	2000 mg	
Doxorubicin Intravesical	150 mg	None
Doxorubicin Intra-Arterial	150 mg	None
Estramustine Oral	2520 mg/day	
Everolimus Oral Suspension	25 mg	
Interferon Alfa-2B IV	75 million units	
Interferon Alfa-2B Subcutaneous	75 million units	
Methotrexate IM	None	
Methotrexate (PF) IM	None	
Methotrexate Subcutaneous	None	
Methotrexate (PF) Subcutaneous	None	
Methotrexate (PF) Subcutaneous Auto-Injector	None	5 mg
Ondansetron (PF) IV	16 mg	
Pegaspargase IM	6250 units	50 units
Pegaspargase Subcutaneous	6250 units	50 units
Pegaspargase IV	6250 units	50 units
Sargramostim Subcutaneous	625 mcg	

Drug Name	New Maximum Single Dose	Rounding Rule
Sargramostim IV	625 mcg	
Thiotepa Intravesical	None	
Tocilizumab Subcutaneous Pen Injector	162 mg	
Tofacitinib Oral	10 mg; 20 mg/day	
Topotecan Intrathecal	None	
Vedolizumab IV	300 mg	
Vincristine Liposomal IV	5.6 mg	0.1 mg

Regimens

Updates

Vinca Alkaloid IV Push Removal

Based on [FDA recommendations](#), vinca alkaloid orders given by IV push are removed from all McKesson regimen templates with this release on 3/31/2021.

Infection Prophylaxis

To reduce risk for unintentional omission, the Collaborative Care Committee (CCC) voted to include standardized HSV/VZV and PJP prophylaxis in regimens with drugs at high risk for infection. These changes will be made over several months.

Ferumoxylol (Feraheme) Infusion Length

Due to risk for infusion-related reactions, CCC voted to change the Feraheme infusion length from “15 minutes” to “over at least 30 minutes”.

Biosimilars

Added Rituximab-arrx (Riabni) and pegfilgrastim-apgf (Nyvepria) as optional orders in applicable regimen templates.

Diagnosis Regimen Updates

CCC voted to change the regimens for the diagnoses below. Changes include but are not limited to updates to references, infusion instructions, regimen names, premedication templates and number of cycles.

- All Problems
- Amyloidosis
- Basal cell carcinoma
- Breast Cancer
- Fallopian Tube Cancer
- Hepatocellular Carcinoma (HCC)
- Leukemia, Acute Lymphocytic (ALL)
- Leukemia, Acute Myeloid (AML)

- Leukemia, Chronic Lymphocytic (CLL)
- Leukemia, Chronic Myeloid (CML)
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Multiple Myeloma (MM)
- Ovarian and Primary Peritoneal Cancer
- Prostate Cancer
- Squamous Cell Carcinoma

Additions

The following regimens are now available for ordering in the Regimen Library.

- Anastrozole Q30D (Ovarian)
- Atezolizumab + Bevacizumab BIOSIMILAR + Paclitaxel + Carboplatin Q21D (Part 1 of 2: Induction)
- Atezolizumab + Bevacizumab BIOSIMILAR + Paclitaxel + Carboplatin Q21D (Part 2 of 2: Atezolizumab + Bevacizumab Maintenance)
- Capecitabine D1-14 + Margetuximab-cmkb Q21D
- Daratumumab IV + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (MM) (Part 1 of 2: C1 Split Dosing)
- Daratumumab IV + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (Amyloidosis) (Part 1 of 2: C1 Split Dosing)
- Daratumumab IV + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (Amyloidosis) (Part 1 of 2)
- Daratumumab IV + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (Amyloidosis) (Part 2 of 2: Daratumumab IV only)
- Daratumumab IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q21D (Part 1 of 2: C1 Split Dosing)
- Daratumumab IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q21D (Part 1 of 2)
- Daratumumab IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q28D (Part 2 of 2: Daratumumab IV + Lenalidomide Maintenance)
- Darolutamide + Goserelin Q3M
- Darolutamide + Leuprolide Q3M
- Eribulin D1,8 + Margetuximab-cmkb Q21D
- Gemcitabine D1,8 + Margetuximab-cmkb Q21D
- Letrozole Q30D (Ovarian)
- Melphalan flufenamide + Dexamethasone D1,8,15,22 Q28D
- Tepotinib Q30D
- Trilaciclib Q21D
- Umbralisib Q30D
- Vinorelbine D1,8 + Margetuximab-cmkb Q21D

Regimen Inactivations

The following regimens are no longer available for ordering in the Regimen Library.

- Clofarabine D1-5 (Consolidation) Q28D
- Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV (FCR) (NHL) Q28D
- Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV f/b SQ (FCR) (NHL) Q28D
- Rituximab IV + Fludarabine D2-4 + Cyclophosphamide D2-4 + Mitoxantrone D2 Q28D (R-FCM)

Regimen Renames

Previous Name	New Name
Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV (FCR) (CLL) Q28D	Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV (FCR) Q28D (CLL)
Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV BIOSIMILAR (FCR) (CLL) Q28D	Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV BIOSIMILAR (FCR) Q28D (CLL)
Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV f/b SQ (FCR) (CLL) Q28D	Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV fb SQ (FCR) Q28D (CLL)
Vitamin B12 Pre-Pemetrexed	Vitamin B12 with Pemetrexed

Research

Regimen Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research are migrated and modified for iKnowMed EHR (Generation 1) customers.

Updates

Vinca Alkaloid IV Push Removal

Based on [FDA recommendations](#), vinca alkaloid orders given by IV push are removed from all McKesson regimen templates with this release on 3/31/2021.

Biosimilars

Added Rituximab-arrx (Riabni) and pegfilgrastim-apgf (Nyvepria) as optional orders in applicable regimen templates.

USOR Clinical Trial Updates

	Updated Reference Information			
	Updated Drug Service Order Information		Other Changes	
	Updated Regimen Instructions			
USOR 16065	X	X	The following regimen is now available for ordering: USOR 16065 Umbralisib (TGR-1202) Ramp-Up/Intermittent Dosing	
USOR 16104			The following regimen is no longer available for ordering: USOR 16104 Part E SGN-LIV1A D1,8,15 Q21D	

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 18057	X	X	X	The following regimens are now available for ordering: USOR 18057 Part 2A Arm F BMS-986249 + Nivolumab Q28D USOR 18057 Part 2B BMS-986249 D1 + Nivolumab D1,29 Q56D
USOR 18097	X	X	X	
USOR 18234		X		
USOR 18261	X		X	Sponsor confirmed use of bevacizumab biosimilars is allowed; The following regimens are now available for ordering: USOR 18261 Arm C FOLFOX + Bevacizumab BIOSIMILAR USOR 18261 Arm C FOLFIRI + Bevacizumab BIOSIMILAR
USOR 19221	X	X	X	
USOR 20150	X		X	
USOR 20178	X			
USOR 20189		X		
USOR 20218	X		X	
USOR 20297	X		X	

Billing: HCPCS Code Updates

Medication	HCPCS Code
Belantamab mafodotin-blmf, inj	J9037 per 0.5 mg
Brexucabtagene autoleucel, inj	Q2053 per 68 mL
Cabotegravir-Rilpivirine IM ER Susp 200 mg/mL-300 mg/mL (Cabenuva)	J3490 per 4 mL J3490 per 6 mL
Casirivimab/imdevimab, inj	Q0243 per 2400 mg
Fluoroestradiol F-18 IV 148 MBq/mL to 3,700 MBq/mL	A9591 per 1 mCi
Fremanezumab-vfrm Subcutaneous Auto-Injector	J3031 per 1 mg
Gallium Ga-68 Dotatoc IV 18.5 MBq to 148 MBq/mL	A9587 per 0.1 mCi
Immune globulin,gamma(igg)slra, inj	J1554 per 500 mg
Lutetium Lu 177 Dotatate IV 10 mCi/mL (370 mBq/mL)	A9513 per 1 mCi

Medication	HCPSC Code
Margetuximab-cmkb IV	J3590 per 250 mg
Melphalan Flufenamide IV	J9999 per 20 mg
Mometasone furoate	J7402 per 10 mcg
Ondansetron Continuous Subcutaneous Infusion	J2405 per 1 mg
Ondansetron (PF) Continuous Subcutaneous Infusion	J2405 per 1 mg
Pertuzumab-Trastuzumab-Hy-zzxf Subcutaneous 1200 mg-600 mg-30,000 unit/15 mL (Phesgo)	J9316 per 0.0834 mL J9316 per 6.67 mg
Pertuzumab-Trastuzumab-Hy-zzxf Subcutaneous 600 mg-600 mg-20,000 unit/10 mL (Phesgo)	J9316 per 0.084 mL J9316 per 10 mg
Sodium Fluoride F-18 IV 10 mCi to 200 mCi/mL	A9580 per 30 mCi
Tafasitamab-cxix, inj	J9349 per 2 mg
Trilaciclib IV	J3490 per 300 mg
Viltolarsen, inj	J1427 per 10 mg